Inventiva declares results of Phase IIb clinical trial of lanifibranor
Category: #health  By Mateen Dalal  Date: 2019-02-19
  • share
  • Twitter
  • Facebook
  • LinkedIn

Inventiva declares results of Phase IIb clinical trial of lanifibranor

The FASST clinical trial failed to meet its primary endpoint of a mean absolute change from baseline to week 48

The French clinical-stage biopharmaceutical firm Inventiva has reportedly declared the results from the ‘For A Systemic Sclerosis Treatment’ (FASST) clinical trial assessing lanifibranor for the treatment of diffuse cutaneous systemic sclerosis (dcSSc). As per trusted sources, the FASST clinical trial failed to meet its primary endpoint of a mean absolute change from baseline to week 48.

Reportedly, the FASST clinical trial included 145 patients suffering from the initial phase of dcSSc. These patients received lanifibranor in either two dosages of 600mg each day or two dosages of 400mg each day over a period of 48 weeks. Sources familiar with the matter claim that the dosages were in addition to the existing standard of care and included immunosuppressive therapy in most cases. For the record, the FASST clinical trial is a placebo-controlled, randomized, double-blind, one-year Phase IIb study.

Co-principal investigator of the FASST clinical trial and professor of rheumatology at the Hôpital Cochin in Paris, Yannick Allanore was reportedly quoted saying that the trail characterizes the first study in dcSSc with a stratified background on immunosuppressive therapy. Allanore further added that the presence of background therapy created a strong placebo effect and restricted the number of patients making progress in dcSSc.

According to a press release issued by Inventiva, over the course of the trial, the average mRSS declined in active and placebo arms with only four patients reporting to have observed increase in mRSS scores.

Co-principal investigator of the FASST clinical trial and professor at the University College of London, Christopher Denton reportedly commented that the team regrets the outcome of the study. However, lanifibranor’s favorable safety profile observed in the trial and the well-being of lanifibranor patients expressed in the global assessment has been a gratifying experience for the team.

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Taco Bell to introduce its first-ever business school for employees
Taco Bell to introduce its first-ever business school for employees
By Mateen Dalal

The fast-food chain has collaborated with the University of Louisville for starting this project Taco Bell, a US-based chain of fast-food restaurants, is reportedly opening its business school with a vision of helping its employees learn the skills ...

Jubilant Foodworks unveils first chain of Popeyes in Bengaluru, India
Jubilant Foodworks unveils first chain of Popeyes in Bengaluru, India
By Mateen Dalal

Jubilant Foodworks Ltd, an Indian food service company, has recently announced unveiling the iconic United States’ Fried Chicken brand-Popeyes in India by inaugurating its first store in Bengaluru, India. For the uninitiated, Popeyes Louisiana...

Affinity to trade Burger King business in Japan & South Korea for $1Bn
Affinity to trade Burger King business in Japan & South Korea for $1Bn
By Mateen Dalal

Affinity Equity Partners, one of the largest dedicated Asian private equity firms, is reportedly planning to sell off its Burger King fast-food businesses in Japan and South Korea, in a deal that can offer more than $1 billion, said a credible source...